Skip to main content

Table 3 Factors for predicting the overall survival

From: Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis

Factors

 

Median survival

P-value

  

(months)

 

Age (yrs)

≤60

9.8 ± 4.9

0.585

 

>60

13.6 ± 2.1

 

Gender

Male

12.9 ± 1.9

0.293

 

Female

11.6 ± 1.0

 

ECOG

1

15.9 ± 4.0

0.070

 

2

9.8 ± 3.1

 

Etiology

Viral

11.3 ± 1.4

0.344

 

Non-viral

13.6 ± 2.2

 

Child-Pugh

A

13.0 ± 1.5

0.309

Classification

B

6.4 ± 0.8

 

JIS score

2

13.0 ± 1.4

0.235

 

3

5.8 ± 0.3

 

Pretreatment

≤ 20

15.9 ± 1.6

0.161

AFP (ng/ml)

> 20

10.9 ± 1.0

 

Type of HCC

Nodular

11.3 ± 0.7

0.853

 

Diffuse infiltrative

13.6 ± 4.4

 

Multiplicity

Solitary

11.3 ± 1.3

0.534

 

Multiple

13.9 ± 2.1

 

Location of thrombi

PV branch

16.6 ± 5.9

0.036

 

Main portal trunk

9.8 ± 4.2

 

BED (Gy10)

< 75

13.0 ± 1.4

0.901

 

≥ 75

9.8 ± 4.7

 

PVTT response

CR + PR

13.9 ± 1.1

0.142

 

SD + PD

6.9 ± 5.1

 
  1. Abbreviations: ECOG, Eastern Cooperative Oncology Group; JIS, Japan integrated staging; AFP, α-fetoprotein; HCC, Hepatocellular carcinoma; PV, Portal vein; BED, biologically effective dose; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
  2. P-values are obtained by log-rank test.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us